Reviewer's report

Title: Celecoxib Concentration Predicts Decrease In Prostaglandin E2 Concentrations In Nipple Aspirate Fluid From High Risk Women

Version: 1 Date: 4 June 2007
Reviewer: Masakazu Toi

Reviewer's report:

General
It is an interesting study focusing upon PGE2 levels in NAF and plasma of the high-risk women treated with celecoxib. Recent studies have elucidated that NAF is important to monitor the therapeutic impact of preventive agents for breast cancer. It is also useful to look at influences of hormones in breast duct in situ.

-------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

- It is required to explain further about the difference in the suppression of PGE2 in NAF by celecoxib between premenopausal and postmenopausal women. For instance, a question may arise that menstruation cycle may influence on the PGE2 levels and its suppression by COX inhibition. In addition, a concern might be raised that assay system might be influenced by menopausal status, which is obviously crucial for this study. More explanations are essentially requested.

-------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

- The details of NAF collection should be clarified in more depth, because the procedure methodology might affect on the concentration levels.

-------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after discretionary revisions
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.